Many of the 300,000 HCV-infected Canadians live in under-served and remote areas without access to HCV healthcare specialists. Telemedicine (TM) and advances in HCV management can facilitate linkage of these marginalized patients to healthcare.

The TM program described comprises a population that faces many barriers to effective HCV treatment – genotype 3 (25.9% vs. 16.4%),  Indigenous (7.0% vs. 2.2%)  history of injection drug use (70.1% vs. 54.9%) and incarceration (46.5% vs 35.5%).

The study found TM patients initiated HCV therapy and achieved High SVR rates comparable to those obtained using traditional models of care.

Read the complete report here: